Drugs that contain Sodium Phenylbutyrate; Taurursodiol
1. List of Relyvrio drug patents
RELYVRIO's oppositions filed in EPO
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10857162 | AMYLYX | Compositions for improving cell viability and methods of use thereof |
Dec, 2033
(10 years from now) | |
| US10251896 | AMYLYX | Compositions for improving cell viability and methods of use thereof |
Dec, 2033
(10 years from now) | |
| US9872865 | AMYLYX | Compositions for improving cell viability and methods of use thereof |
Dec, 2033
(10 years from now) | |
| US11071742 | AMYLYX | Compositions for improving cell viability and methods of use thereof |
Dec, 2033
(10 years from now) | |
| US11583542 | AMYLYX | NA |
Jul, 2040
(17 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Sep 29, 2027 |
NCE-1 date: 2026-09-29
Market Authorisation Date: 29 September, 2022
Treatment: Treatment of amyotrophic lateral sclerosis (als) in adults
Dosage: FOR SUSPENSION;ORAL
More Information on Dosage
RELYVRIO family patents
9
United States
5
Korea, Republic of
4
Australia
4
Japan
3
China
2
European Union
1
Portugal
1
Slovenia
1
Croatia
1
ME
1
Hungary
1
Hong Kong
1
Poland
1
RS
1
Denmark
1
Canada
1
Lithuania
1
Spain
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic